Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -110.24% is 107% below its 5-year average of -53.38%, near the low end of its 5-year range (-110.24%–-22.97%).
42.88% below its 12-month average of -77.16%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -46.39%.
RETURN ON ASSETS (ROA)
-110.24%
RETURN ON ASSETS (ROA) AVG TTM
-77.16%
RETURN ON ASSETS (ROA) AVG 3Y
-67.85%
RETURN ON ASSETS (ROA) AVG 5Y
-53.38%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-42.88%
CURRENT VS 3Y AVG
-62.47%
CURRENT VS 5Y AVG
-106.51%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-241.67%
vs the sector median at left
Tenaya Therapeutics, Inc.
Market Cap
$118.59M
Return on Assets (ROA)
-110.24%
TTM Avg
-77.16%
3Y Avg
-67.85%
5Y Avg
-53.38%
Market Cap
$118.83M
Return on Assets (ROA)
-53.26%
TTM Avg
-24.98%
3Y Avg
-43.10%
5Y Avg
-143.56%
Market Cap
$117.76M
Return on Assets (ROA)
-49.93%
TTM Avg
-95.40%
3Y Avg
-72.70%
5Y Avg
-57.07%
Market Cap
$119.84M
Return on Assets (ROA)
-31.33%
TTM Avg
-56.73%
3Y Avg
-59.49%
5Y Avg
-64.55%
Market Cap
$120.41M
Return on Assets (ROA)
-26.48%
TTM Avg
-24.24%
3Y Avg
-21.83%
5Y Avg
-17.99%
Market Cap
$116.76M
Return on Assets (ROA)
-19.30%
TTM Avg
-19.59%
3Y Avg
-15.38%
5Y Avg
-15.18%
Market Cap
$120.58M
Return on Assets (ROA)
-1.70%
TTM Avg
-35.34%
3Y Avg
-51.03%
5Y Avg
-36.99%
Market Cap
$115.67M
Return on Assets (ROA)
-31.75%
TTM Avg
-34.00%
3Y Avg
-32.33%
5Y Avg
-29.29%
Market Cap
$122.43M
Return on Assets (ROA)
-4.60%
TTM Avg
-3.66%
3Y Avg
-5.21%
5Y Avg
-1.02%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tenaya Therapeutics, Inc. (TNYA) | $118.59M | -110.24% | -77.16% | -67.85% | -53.38% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.83M | -53.26% | -24.98% | -43.10% | -143.56% |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | -49.93% | -95.40% | -72.70% | -57.07% |
| Cibus, Inc. (CBUS)vs › | $119.84M | -31.33% | -56.73% | -59.49% | -64.55% |
| Seer, Inc. (SEER)vs › | $120.41M | -26.48% | -24.24% | -21.83% | -17.99% |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | -19.30% | -19.59% | -15.38% | -15.18% |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | -1.70% | -35.34% | -51.03% | -36.99% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | -31.75% | -34.00% | -32.33% | -29.29% |
| BGM Group Ltd. (BGM)vs › | $122.43M | -4.60% | -3.66% | -5.21% | -1.02% |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $122.66M | -62.84% | -62.29% | -62.24% | -56.44% |
ROA
-110.2%
ROE
-148.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -61.66% |
| 2024-12-31 | -92.65% |
| 2023-12-31 | -72.77% |
| 2022-12-31 | -44.33% |
| 2021-12-31 | -22.97% |
| 2020-12-31 | -25.91% |
| 2019-12-31 | -67.84% |
